News Ethics and Policy Operational Efficiency Decision-Making Support Head and Neck Cancer

How Federal Regulatory Strategies Are Spurring Innovation in the Use of AI in Cancer Care

In an interview, Travis J. Osterman, DO, MS, FAMIA, FASCO, discusses current regulatory strategies surrounding the use and advancement of AI in oncology practice and the priorities of AI in cancer care for the next several years.

April 29, 2026 By Jo Cavallo 11 min read
Share

Clinical Scorecard: How Federal Regulatory Strategies Are Spurring Innovation in the Use of AI in Cancer Care

At a Glance

CategoryDetail
ConditionCancer Care
Key MechanismsAI-enabled devices and augmented reality for treatment decision-making and surgical assistance.
Target PopulationPatients with cancer, particularly those in rural communities.
Care SettingOncology clinics and surgical settings.

Key Highlights

  • FDA guidance on predetermined change control plans (PCCPs) facilitates AI device updates.
  • Augmented reality systems are being developed to assist in tumor resections.
  • AI integration in treatment decision-making is ongoing, with a focus on unbiased models.
  • The guidance aims to reduce barriers to innovation in oncology care.
  • There is a need to balance regulation with the urgency of patient care access.

Guideline-Based Recommendations

Diagnosis

  • Utilize AI models for improved diagnostic accuracy in oncology.

Management

  • Implement AI-enabled devices with PCCPs to ensure ongoing safety and effectiveness.

Monitoring & Follow-up

  • Regularly assess AI model performance and updates post-approval.

Risks

  • Monitor for algorithm bias and ensure equitable access to AI technologies.

Patient & Prescribing Data

Patients with various types of cancer, including those in rural areas.

AI can enhance treatment decision-making and reduce the burden of travel for patients.

Clinical Best Practices

  • Adopt augmented reality technologies for surgical precision.
  • Ensure continuous updates and improvements to AI models.
  • Facilitate access to AI technologies in community cancer centers.

References

ASCO AI in Oncology is published by Conexiant under a license arrangement with the American Society of Clinical Oncology, Inc. (ASCO®). The ideas and opinions expressed in ASCO AI in Oncology do not necessarily reflect those of Conexiant or ASCO. For more information, see Policies.

KOL Commentary
Watch

Related Content